New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
05:36 EDTBAYRY, REGNRegeneron, Bayer submit Eylea Injection for EU marketing authorization
Regeneron Pharmaceuticals (REGN) and Bayer HealthCare (BAYRY) announced that Bayer HealthCare has submitted an application to the European Medicines Agency seeking marketing authorization in the European Union for Eylea Injection for the treatment of macular edema following branch retinal vein occlusion, or BRVO. The EMA submission is based on the positive Phase 3 VIBRANT trial, a double-masked, randomized, active-controlled study of patients with macular edema following BRVO. In the VIBRANT study, 53% of patients who received EYLEA 2 milligram monthly gained at least 15 letters in best-corrected visual acuity, or BCVA, from baseline at week 24, the primary endpoint of the study, compared to 27 of patients who received laser, a standard of care treatment. In addition, EYLEA met a key secondary endpoint, achieving a 17.0 letter mean improvement over baseline in BCVA compared to a 6.9 letter mean improvement in patients who received laser.
News For REGN;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
08:11 EDTBAYRYFoamix earns $2.5M milestone payment from Bayer
Subscribe for More Information
December 12, 2014
08:01 EDTREGNPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 10, 2014
07:56 EDTBAYRYUBS to hold a conference
Agriculture Investor Day is being held in Chicago on December 10.
December 9, 2014
12:22 EDTBAYRYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:23 EDTBAYRYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:38 EDTBAYRYBayer downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
December 4, 2014
08:45 EDTBAYRYAbbVie price target raised to $80 from $72 at Jefferies
Jefferies raised its price target for AbbVie shares to $80 while calling the company one of its top five global pharma picks for 2015. The firm's top U.S. pick is Pfizer (PFE) and its top Europe pick is Novartis (NVS). Bayer (BAYRY) and AstraZeneca (AZN) round out the top five. Jefferies thinks AbbVie's "strong momentum" will continue into the first half of 2015 and keeps a Buy rating on the name.
06:47 EDTREGNRegeneron removed from Top Picks List at Credit Suisse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use